Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk

Despite recent advances in the development of tools to predict immunogenicity risk of biotherapeutic molecules, the ability of a protein to elicit the formation of anti-drug antibodies (ADA) remains one of the most common causes for termination of clinical development programs. In this study, we use...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:MAbs
Asıl Yazarlar: Bivi, Nicoletta, Moore, Terry, Rodgers, George, Denning, Heather, Shockley, Travis, Swearingen, Craig A., Gelfanova, Valentina, Calderon, Boris, Peterson, Daniel A., Hodsdon, Michael E., Siegel, Robert W., Higgs, Richard E., Konrad, Robert J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2019
Konular:
Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6601536/
https://ncbi.nlm.nih.gov/pubmed/31099718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1612699
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller